JP2022511800A5 - - Google Patents

Info

Publication number
JP2022511800A5
JP2022511800A5 JP2021531047A JP2021531047A JP2022511800A5 JP 2022511800 A5 JP2022511800 A5 JP 2022511800A5 JP 2021531047 A JP2021531047 A JP 2021531047A JP 2021531047 A JP2021531047 A JP 2021531047A JP 2022511800 A5 JP2022511800 A5 JP 2022511800A5
Authority
JP
Japan
Prior art keywords
theta
crystal morphology
crystal
xrpd
pattern
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021531047A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022511800A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/064784 external-priority patent/WO2020118113A1/en
Publication of JP2022511800A publication Critical patent/JP2022511800A/ja
Publication of JP2022511800A5 publication Critical patent/JP2022511800A5/ja
Priority to JP2024188449A priority Critical patent/JP2025026857A/ja
Pending legal-status Critical Current

Links

JP2021531047A 2018-12-06 2019-12-05 痛風または高尿酸血症を処置または予防するための化合物の結晶形態 Pending JP2022511800A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024188449A JP2025026857A (ja) 2018-12-06 2024-10-25 痛風または高尿酸血症を処置または予防するための化合物の結晶形態

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2018119567 2018-12-06
CNPCT/CN2018/119567 2018-12-06
PCT/US2019/064784 WO2020118113A1 (en) 2018-12-06 2019-12-05 Crystalline forms of a compound for treating or preventing gout or hyperuricemia

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024188449A Division JP2025026857A (ja) 2018-12-06 2024-10-25 痛風または高尿酸血症を処置または予防するための化合物の結晶形態

Publications (2)

Publication Number Publication Date
JP2022511800A JP2022511800A (ja) 2022-02-01
JP2022511800A5 true JP2022511800A5 (cg-RX-API-DMAC7.html) 2022-12-12

Family

ID=70974392

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021531047A Pending JP2022511800A (ja) 2018-12-06 2019-12-05 痛風または高尿酸血症を処置または予防するための化合物の結晶形態
JP2024188449A Pending JP2025026857A (ja) 2018-12-06 2024-10-25 痛風または高尿酸血症を処置または予防するための化合物の結晶形態

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024188449A Pending JP2025026857A (ja) 2018-12-06 2024-10-25 痛風または高尿酸血症を処置または予防するための化合物の結晶形態

Country Status (12)

Country Link
US (2) US12145917B2 (cg-RX-API-DMAC7.html)
EP (1) EP3890723A4 (cg-RX-API-DMAC7.html)
JP (2) JP2022511800A (cg-RX-API-DMAC7.html)
KR (1) KR102946486B1 (cg-RX-API-DMAC7.html)
CN (1) CN113226302B (cg-RX-API-DMAC7.html)
AU (1) AU2019394974B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021010708A2 (cg-RX-API-DMAC7.html)
EA (1) EA202191545A1 (cg-RX-API-DMAC7.html)
IL (1) IL283663B2 (cg-RX-API-DMAC7.html)
SG (1) SG11202105745UA (cg-RX-API-DMAC7.html)
TW (1) TWI828817B (cg-RX-API-DMAC7.html)
WO (1) WO2020118113A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170110083A (ko) 2014-12-23 2017-10-10 인털렉츄얼 프라퍼티 어쏘시에이츠, 엘엘씨 경피 투여를 위한 방법 및 제형
AU2017298142B2 (en) 2016-07-18 2021-11-11 Arthrosi Therapeutics, Inc. Compounds, compositions and methods for treating or preventing a symptom associated with gout or hyperuricemia
EP4324460A3 (en) 2017-09-15 2024-04-24 Dyve Biosciences, Inc. Sodium bicarbonate for use in the treatment of gout and related disorders
CN113164439A (zh) 2018-12-06 2021-07-23 安索治疗公司 用于治疗或预防痛风或高尿酸血症的方法
JP2022511800A (ja) 2018-12-06 2022-02-01 アースローシ セラピューティクス,インク. 痛風または高尿酸血症を処置または予防するための化合物の結晶形態
CA3140412A1 (en) * 2019-05-14 2020-11-19 Arthrosi Therapeutics, Inc. Compound for treating gout or hyperuricemia
KR20230024354A (ko) * 2020-06-10 2023-02-20 아쓰로시 테라퓨틱스, 인크. 만성 신장 질환을 치료 또는 예방하는 방법
WO2023098872A1 (en) * 2021-12-02 2023-06-08 Arthrosi Therapeutics, Inc. Crystalline forms of a compound for treating or preventing gout or hyperuricemia
WO2023125667A1 (en) * 2021-12-30 2023-07-06 Arthrosi Therapeutics, Inc. Preparation of a compound for the treatment of gout or hyperuricemia

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4624848A (en) 1984-05-10 1986-11-25 Ciba-Geigy Corporation Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
US4968509A (en) 1987-07-27 1990-11-06 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
IL92966A (en) 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
ES2111065T5 (es) 1991-04-16 2005-06-16 Nippon Shinyaku Company, Limited Procedimiento para producir una dispersion solida.
CZ282760B6 (cs) 1991-11-22 1997-09-17 Procter And Gamble Pharmaceuticals, Inc. Risedronátové prostředky se zpožděným uvolňováním
US5461140A (en) 1992-04-30 1995-10-24 Pharmaceutical Delivery Systems Bioerodible polymers for solid controlled release pharmaceutical compositions
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
WO1994008568A1 (fr) 1992-10-16 1994-04-28 Nippon Shinyaku Co., Ltd. Procede pour fabriquer des matrices de cire
US5686105A (en) 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
KR19990014865A (ko) 1995-05-17 1999-02-25 피터 이. 브래이브맨 소장에서의 소화 및 흡수를 증진시키기 위한, 지방산을 함유한조성물들
DE19624292A1 (de) 1996-06-18 1998-01-02 Merckle Gmbh Verfahren und Zwischenprodukte zur Herstellung von 1'-Hydroxybenzbromaron
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6465014B1 (en) 2001-03-21 2002-10-15 Isp Investments Inc. pH-dependent sustained release, drug-delivery composition
EP1767531A4 (en) 2004-06-10 2011-01-05 Torii Pharmaceutical Co Ltd 6-HYDROXYBENZBROMARONE OR SALTING MEDICAL COMPOSITIONS CONTAINING THEREOF
US20080305169A1 (en) 2006-05-26 2008-12-11 Japan Tobacco Inc. Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds
EP2139848A1 (en) 2007-04-26 2010-01-06 Auspex Pharmaceuticals, Inc. Deuterium labelled ketamine
TWI377944B (en) 2007-06-05 2012-12-01 Hanmi Holdings Co Ltd Novel amide derivative for inhibiting the growth of cancer cells
EP2291189B1 (en) 2008-05-22 2014-10-01 AstraZeneca AB Method for treating hyperuricemia employing an sglt2 inhibitor and composition containing same
JP5325065B2 (ja) 2009-09-30 2013-10-23 株式会社富士薬品 新規フェノール誘導体
IT1400609B1 (it) 2010-05-10 2013-06-14 Menarini Int Operations Lu Sa Associazione di inibitori della xantina ossidasi e metformina e loro uso.
US10005750B2 (en) 2010-10-06 2018-06-26 J-Pharma Co., Ltd. Developing potent urate transporter inhibitors: compounds designed for their uricosuric action
US20150031768A1 (en) 2011-08-19 2015-01-29 The Trustees Of Princeton University C-halogen bond formation
US9060987B2 (en) * 2011-11-04 2015-06-23 Cymabay Therapeutics, Inc. Methods for treating gout flares
US9962362B2 (en) 2012-03-29 2018-05-08 Children's Hospital Medical Center Use of small molecule inhibitors targeting EYA tyrosine phosphatase
MA37711A1 (fr) * 2012-06-04 2017-05-31 Pharmacyclics Inc Formes cristallines d'un inhibiteur de tyrosine kinase de bruton
WO2014113407A2 (en) 2013-01-16 2014-07-24 Children's Hospital Medical Center Use of small molecule inhibitors targeting eya tyrosine phosphatase
WO2014149789A1 (en) 2013-03-15 2014-09-25 Janssen Pharmaceutica Nv Combination of canagliflozin and probenecid for the treament of hyperuricemia
JP2016520133A (ja) 2013-05-31 2016-07-11 タケダ ファーマシューティカルズ ユー.エス.エー. インコーポレイティド キサンチンオキシダーゼ阻害剤を用いた治療方法及びそれを含む組成物
WO2015134467A1 (en) 2014-03-05 2015-09-11 The Trustees Of Princeton University Methods and compositions for direct radioactive labeling of bio-active molecules and building blocks
US9546166B2 (en) 2014-07-31 2017-01-17 Merck Patent Gmbh Indolizine derivatives and their use in neurodegenerative diseases
CN104262305B (zh) * 2014-09-16 2016-06-08 东北制药集团股份有限公司 一种苯溴马隆晶型a及其制备方法
CN104311516B (zh) * 2014-09-16 2017-01-11 东北制药集团股份有限公司 一种苯溴马隆晶型b及其制备方法
AU2017298142B2 (en) 2016-07-18 2021-11-11 Arthrosi Therapeutics, Inc. Compounds, compositions and methods for treating or preventing a symptom associated with gout or hyperuricemia
WO2018090921A1 (zh) 2016-11-16 2018-05-24 江苏新元素医药科技有限公司 Urat1抑制剂及其应用
WO2018110887A1 (ko) 2016-12-14 2018-06-21 주식회사 엘지화학 헤테로 고리 화합물 및 이를 포함하는 유기 발광 소자
WO2019195118A1 (en) 2018-04-03 2019-10-10 Children's Hospital Medical Center Inhibitors of eya3-protein tyrosine phosphatase in dna damage repair signaling of pulmonary arterial hypertension
WO2019233459A1 (zh) 2018-06-08 2019-12-12 江苏威凯尔医药科技有限公司 人表皮生长因子受体抑制剂及其制备方法和应用
WO2020070539A1 (en) 2018-10-01 2020-04-09 Astrazeneca Ab Compositions for reducing serum uric acid
JP2022511800A (ja) 2018-12-06 2022-02-01 アースローシ セラピューティクス,インク. 痛風または高尿酸血症を処置または予防するための化合物の結晶形態
CN113164439A (zh) 2018-12-06 2021-07-23 安索治疗公司 用于治疗或预防痛风或高尿酸血症的方法
US11365189B2 (en) 2019-04-25 2022-06-21 Board Of Regents, The University Of Texas System Heterocyclic inhibitors of tyrosine kinase
CA3140412A1 (en) 2019-05-14 2020-11-19 Arthrosi Therapeutics, Inc. Compound for treating gout or hyperuricemia
CN112079830B (zh) 2019-06-14 2023-12-22 上海翰森生物医药科技有限公司 含并环类衍生物抑制剂、其制备方法和应用
KR20230024354A (ko) 2020-06-10 2023-02-20 아쓰로시 테라퓨틱스, 인크. 만성 신장 질환을 치료 또는 예방하는 방법
CN111763215B (zh) 2020-07-21 2021-05-18 成都海博为药业有限公司 一种具有含氮杂环结构的化合物及其制备方法和用途
CN112729156A (zh) 2020-12-24 2021-04-30 上海智能制造功能平台有限公司 一种人体数字化测量装置的数据拼接及系统标定方法
CN114697265A (zh) 2020-12-29 2022-07-01 华为技术服务有限公司 一种报文处理方法及装置
WO2023028054A1 (en) 2021-08-24 2023-03-02 Arthrosi Therapeutics, Inc. Quinazoline compounds for treatment of disease
WO2023098872A1 (en) * 2021-12-02 2023-06-08 Arthrosi Therapeutics, Inc. Crystalline forms of a compound for treating or preventing gout or hyperuricemia
WO2023125667A1 (en) 2021-12-30 2023-07-06 Arthrosi Therapeutics, Inc. Preparation of a compound for the treatment of gout or hyperuricemia

Similar Documents

Publication Publication Date Title
JP2022507251A5 (cg-RX-API-DMAC7.html)
JP2021530565A5 (cg-RX-API-DMAC7.html)
FI4058151T3 (fi) Terfenyyliyhdisteen uusi suola
JP2018024682A5 (cg-RX-API-DMAC7.html)
FI3880678T3 (fi) P2x3-muuntaja metyyli-(s)-2-((2-(2,6-difluori-4-(metyylikarbamoyyli)fenyyli)-7-metyyli-imidatso[1,2-a]pyridin-3-yyli)metyyli)morfoliini-4-karboksylaatin kidemuotoja
JP2018516883A5 (cg-RX-API-DMAC7.html)
JP2007532560A5 (cg-RX-API-DMAC7.html)
JP2012509321A5 (cg-RX-API-DMAC7.html)
JP2016065042A5 (cg-RX-API-DMAC7.html)
JP2018509457A5 (cg-RX-API-DMAC7.html)
JP2013516473A5 (cg-RX-API-DMAC7.html)
JP2014530818A5 (cg-RX-API-DMAC7.html)
JP2016000739A5 (cg-RX-API-DMAC7.html)
JP2013520488A5 (cg-RX-API-DMAC7.html)
CN104011035A (zh) 卡巴他赛的晶型和用于制备其的方法
JP2016539985A5 (cg-RX-API-DMAC7.html)
JP2016537326A5 (cg-RX-API-DMAC7.html)
JP2020502224A5 (cg-RX-API-DMAC7.html)
JP2019532919A5 (cg-RX-API-DMAC7.html)
RU2019105794A (ru) Кристаллогидрат соединения (2s, 3r) -изопропил 2 - (((2- (1,5-диметил-6-оксо-1,6-дигидропиридин-3-ил) -1 - ((тетрагидро-2h-пиран) -4-ил) метил) -1h-бензо [d] имидазол-5-ил) метил) амино) -3-гидроксибутаноат эдисилат
JP2022535072A5 (cg-RX-API-DMAC7.html)
JP2023518399A5 (cg-RX-API-DMAC7.html)
JP2022533958A5 (cg-RX-API-DMAC7.html)
JP2025102940A5 (cg-RX-API-DMAC7.html)
JP2016510767A5 (cg-RX-API-DMAC7.html)